Which diabetes mellitus medicine given in which condition
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
I have comprehensive data from Fuster & Hurst's The Heart (15th Edition) on diabetes pharmacotherapy. Let me now compose the full answer using this textbook data plus my knowledge.
Here is a complete, structured reference for diabetes mellitus medicines and their indications:
Diabetes Mellitus: Medicines and Their Conditions of Use
1. Biguanides - Metformin
| Drug | Brand | Condition / Indication |
|---|---|---|
| Metformin | Glucophage, Glumetza | 1st-line for Type 2 DM (T2D) - primary prevention and treatment |
| Glucophage XR | 2nd-line T2D - when additional control needed |
Key points:
- Drug of choice in overweight/obese T2D patients
- Reduces hepatic glucose output (gluconeogenesis)
- Dose with meals to reduce GI side effects
- Avoid if eGFR < 30 mL/min (hold on surgery day)
- Avoid excess alcohol use
- NOT used in Type 1 DM as primary therapy
2. SGLT2 Inhibitors (Sodium-Glucose Co-Transporter 2 Inhibitors)
| Drug | Brand | Condition / Indication |
|---|---|---|
| Canagliflozin | Invokana | 2nd-line T2D; 1st-line T2D + CVD / Heart Failure / Microalbuminuria |
| Empagliflozin | Jardiance | 2nd-line T2D; 1st-line T2D + CVD / Heart Failure / Microalbuminuria |
| Dapagliflozin | Farxiga | 2nd-line T2D |
| Ertugliflozin | Steglatro | 2nd-line T2D |
Key points:
- Block glucose reabsorption in kidney - glucose lost in urine
- Preferred when T2D is complicated by cardiovascular disease, heart failure, or proteinuric CKD
- Hold for eGFR < 30 mL/min (Ertugliflozin: hold < 60 mL/min)
- Can cause euglycemic DKA - stop before surgery
- HbA1c reduction: 0.5-1.0%
3. GLP-1 Receptor Agonists (Glucagon-Like Peptide-1)
| Drug | Brand | Condition / Indication |
|---|---|---|
| Exenatide | Byetta | 2nd-line T2D; 1st-line T2D + CVD / Obesity / High TG |
| Exenatide XR | Bydureon | 2nd-line T2D; 1st-line T2D + CVD/Obesity/High TG |
| Liraglutide | Victoza | 2nd-line T2D; 1st-line T2D + CVD/Obesity |
| Semaglutide | Ozempic | 2nd-line T2D; 1st-line T2D + CVD / Obesity |
| Dulaglutide | Trulicity | 2nd-line T2D |
Key points:
- Injectable (subcutaneous) agents - stimulate insulin secretion in glucose-dependent manner
- Preferred when T2D is complicated by obesity, cardiovascular disease, or high triglycerides
- Significant weight loss benefit (1-5 kg)
- HbA1c reduction: 1.0-1.5%
- Hold Exenatide if eGFR < 30 mL/min
4. DPP-4 Inhibitors (Dipeptidyl Peptidase-4 Inhibitors / "Gliptins")
| Drug | Brand | Condition / Indication |
|---|---|---|
| Sitagliptin | Januvia | 2nd-line T2D; safe in renal impairment (dose-adjusted) |
| Saxagliptin | Onglyza | 2nd-line T2D |
| Linagliptin | Tradjenta | 2nd-line T2D; no renal dose adjustment needed |
| Alogliptin | Nesina | 2nd-line T2D |
Key points:
- Oral agents, well-tolerated, weight neutral
- Prevent breakdown of endogenous GLP-1
- Useful in elderly patients and those with renal impairment (especially Linagliptin)
- HbA1c reduction: 0.5-0.8%
5. Sulfonylureas (SU)
| Drug | Brand | Condition / Indication |
|---|---|---|
| Glipizide | Glucotrol | 2nd-line T2D; especially when cost is a concern |
| Glimepiride | Amaryl | 2nd-line T2D |
| Glyburide | DiaBeta | 2nd-line T2D (avoid in elderly - long half-life) |
Key points:
- Stimulate pancreatic beta cells to secrete insulin
- Useful when HbA1c reduction > 1% is needed quickly
- Risk of hypoglycemia and weight gain
- Avoid in renal failure (accumulation risk)
- Low cost - preferred in resource-limited settings
- HbA1c reduction: 1.0-1.5%
6. Thiazolidinediones (TZDs / "Glitazones")
| Drug | Brand | Condition / Indication |
|---|---|---|
| Pioglitazone | Actos | 2nd-line T2D; T2D with insulin resistance |
| Rosiglitazone | Avandia | 2nd-line T2D (restricted use - CV concerns) |
Key points:
- Insulin sensitizers - act via PPAR-gamma receptors
- Useful in T2D with significant insulin resistance
- Avoid in heart failure (cause fluid retention)
- Risk of bone fractures and weight gain
- HbA1c reduction: 0.8-1.0%
7. Meglitinides / Glinides
| Drug | Brand | Condition / Indication |
|---|---|---|
| Repaglinide | Prandin | T2D with irregular meal patterns |
| Nateglinide | Starlix | T2D with postprandial hyperglycemia |
Key points:
- Short-acting insulin secretagogues - taken just before meals
- Ideal for patients with erratic schedules
- Less hypoglycemia risk than sulfonylureas
- HbA1c reduction: 0.5-1.0%
8. Alpha-Glucosidase Inhibitors
| Drug | Brand | Condition / Indication |
|---|---|---|
| Acarbose | Precose | T2D with postprandial hyperglycemia; pre-diabetes |
| Miglitol | Glyset | T2D; postprandial control |
Key points:
- Delay carbohydrate digestion in intestine
- Reduce post-meal glucose spikes
- GI side effects (flatulence, diarrhea) limit use
- HbA1c reduction: 0.5-0.8%
9. Insulin - Conditions of Use
| Condition | Type of Insulin Used |
|---|---|
| Type 1 DM (mandatory) | Basal-bolus regimen: long-acting (Glargine/Detemir) + rapid-acting (Lispro/Aspart) |
| Type 2 DM - oral agents failed | Add basal insulin first (Glargine/Detemir), then bolus |
| Gestational DM | Short-acting/intermediate insulin (NPH + Regular) |
| DKA / HHS | IV continuous insulin drip (Regular insulin); lower BG ~100 mg/dL/hr |
| Inpatient/Hospitalized DM | Insulin preferred over oral agents for all DM types |
| Perioperative period | 60-80% of usual basal dose; hold oral agents on surgery day |
| Critically ill patients | IV insulin drip; target glucose 80-180 mg/dL (ICU) |
Insulin types by duration:
| Type | Example | Onset | Duration | Use |
|---|---|---|---|---|
| Rapid-acting | Lispro, Aspart, Glulisine | 5-15 min | 3-5 hr | Mealtime bolus |
| Short-acting | Regular | 30-60 min | 5-8 hr | Meals, DKA drip |
| Intermediate | NPH | 2-4 hr | 12-18 hr | Twice-daily regimens |
| Long-acting | Glargine, Detemir | 1-2 hr | 20-24 hr | Basal once daily |
| Ultra-long | Degludec | 1-2 hr | >42 hr | Flexible dosing |
10. Special Populations - Quick Summary
| Population | Preferred Agent(s) | Avoid |
|---|---|---|
| Obesity | GLP-1 agonists, SGLT2i | Sulfonylureas, TZDs (weight gain) |
| Heart failure | SGLT2i (Empagliflozin) | TZDs, Saxagliptin |
| CKD / Renal impairment | Linagliptin, Insulin | Metformin (eGFR<30), SGLT2i (eGFR<30), Sulfonylureas |
| CVD (atherosclerosis) | GLP-1 agonists, SGLT2i | - |
| Elderly | DPP-4i, Linagliptin, short-acting insulin | Glyburide (long-acting SU) |
| Pregnancy / Gestational DM | Insulin (1st choice), Metformin | All others |
| DKA | IV Insulin drip | All oral agents |
| Type 1 DM | Insulin (mandatory) | Oral agents alone |
Summary Flowchart: T2D Management
Newly diagnosed T2D
|
v
Lifestyle + Metformin (1st line)
|
v
HbA1c not at goal after 3 months?
|
├─ + CVD/HF/CKD → Add SGLT2i or GLP-1 agonist
├─ + Obesity → Add GLP-1 agonist (weight loss)
├─ + Cost concern → Add Sulfonylurea
└─ General → Add DPP-4i or SGLT2i
|
v
Still not at goal → Triple therapy or Add Insulin
Sources: Fuster & Hurst's The Heart, 15th Edition (Table 7-5: Diabetes Pharmacotherapy); Harrison's Principles of Internal Medicine, 22nd Edition (2025)
This is a shared conversation. Sign in to Orris to start your own chat.